| Autor: |
Said, Nora M., Ezzeldin, Nillie, Said, Dina, Ebaid, Amany M., Atef, Dina M., Atef, Rehab M. |
| Zdroj: |
Genes and Immunity; June 2021, Vol. 22 Issue: 2 p93-100, 8p |
| Abstrakt: |
This study was established to assess the effects of IRF5 rs10488631and CD28 rs1980422single-nucleotide polymorphisms (SNPs) and HLA-DRB1shared epitope (SE) allele on the prognosis and disease activity of rheumatoid arthritis (RA) patients. A total of 150 RA patients and 150 healthy controls were genotyped for the selected SNPs by real-time PCR. HLA-DRB1SE was determined using LAB Type SSO Class II DRB1 typing. Our results suggest that HLA-DRB1, CD28, and IRF5significantly discriminated (p< 0.001) RA patients and healthy controls (OR of single HLA-DRB1 SE allele = 2.431, CI = 1.467–4.027, OR of two SE alleles = 11.152, CI = 2.479–50.159), (OR of CD28risk allele C = 2.794, 95% CI = 1.973–3.956) and (OR of IRF5risk allele C = 4.925, CI = 3.26–7.439). Rheumatoid factor (RF) seropositivity was associated with HLA-DRB1SE (p< 0.001) and IRF5risk allele (p< 0.001). ACPA was significantly associated only with IRF5risk allele (p< 0.001). A better response to methotrexate therapy was found in HLA-DRB1SE non-carriers, and CD28TT patients. This study demonstrated associations of HLA-DRB1SE, CD28, and IRF5with the risk of RA. HLA-DRB1SE and CD28 rs1980422can be used as predictors of methotrexate therapy response. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink